The need for a booster vaccine in infants who have acquired universal virus Hepatitis B (HBV) babies remains to be debated. The aim was to discuss the need to improve HBV vaccination and its strategies. In 2009-2010, an 8-year cohort study was carried out in Zhejiang Province of children aged 5–15 years.
Participants were classified into classes A, B and C based on anti-HBs level pre-boosters. Randomly given to children with all markers, 5 μg, 10 μg or 20 μg hepatitis B vaccines or 5 μg hepatitis A and B (HAB). In the first HBV baseline test, blood samples were obtained 1 month after first, 1 month, 1 year, 5 years and 8 years after the third dose. Blood samples of 2326 out of 4170 children had been negative in all markers for HBV. Group II reported the maximum seropositive levels 1 to 8 months after dose 3.
Group C participants had seropositive concentrations of 6519,6 mIU/mla, 5267,4 mIU/ml, 547,1 mIU/ml, 249,5 mIU/mla, 155,3 mIU/ml, respectively after GMTs were re-vaccinated, except 1 month after the third dose of 98,9 percent, 99,5 percent and 95,8 percent, respectively. The 10 μg HBV vaccine will generate vigorous responses and last 8 years or longer with a 0-1-6 month booster scheme.
Reference: https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1738169
